09:30 AM EDT, 06/04/2024 (MT Newswires) -- Bristol-Myers Squibb ( BMY ) said Tuesday that its Phase 3 study assessing the dual immunotherapy combination of Opdivo (nivolumab) and Yervoy (ipilimumab) showed improved survival in patients with unresectable hepatocellular carcinoma, or liver cancer.

The company said the median overall survival of patients treated with Opdivo plus Yervoy was 23.7 months compared with 20.6 months for patients who received lenvatinib or sorafenib.

The combination also demonstrated a higher objective response rate of 36% versus 13% with lenvatinib or sorafenib and a complete response rate of 7% versus 2%, Bristol-Myers said.

The combination therapy also "significantly reduced" risk of symptom deterioration at 24% while its safety profile was consistent with previously reported data, the company added.

Price: 41.85, Change: +0.08, Percent Change: +0.19